Abacavir/lamivudine/zidovudine explained

Abacavir/lamivudine/zidovudine, sold under the brand name Trizivir, is a fixed-dose combination antiretroviral medication for the treatment of HIV/AIDS.^[1] It contains three reverse transcriptase inhibitors patented by GlaxoSmithKline and marketed by a joint venture with Pfizer, ViiV Healthcare:^[2]

• abacavir sulfate (ABC)
• lamivudine (3TC)
• zidovudine (AZT or ZDV)

It is indicated in the treatment of AIDS/HIV-1.^[3] For this purpose, the combination is very useful in pregnant women to decrease the risk of mother-to-child transmission.^[4]

The most common effects include headache and nausea (feeling sick).

Abacavir/lamivudine/zidovudine was approved for use in the United States and the European Union in 2000.^{[5] [6]} In December 2013, Lupin Limited launched a generic version of abacavir/lamivudine/zidovudine.^{[7] [8] [9]}

Side effects

The most common side effects of abacavir/lamivudine/zidovudine include nausea, vomiting, diarrhea, fatigue, paresthesia and headache. As with many medications targeting reverse transcriptase, body fat redistribution syndrome may occur, causing body fat to center on the upper back and neck, breast, and torso, and potentially decreasing around the legs, arms, and face.^[10] IRIS may occur which is when the immune system initially improves, but then deteriorates as a previously ignored infection becomes active. Other serious side effects include:^[11]

• Increased risk of heart attack
• Lactic acidosis
• Severe hepatomegaly
• Lipoatrophy
• Neutropenia
• Anemia
• Hypersensitivity reactions
  • Includes liver failure, renal failure, anaphylaxis, hypotension, and death.

See also

• Abacavir/lamivudine
• Abacavir/dolutegravir/lamivudine

External links

• Web site: Abacavir sulfate mixture with lamivudine and zidovudine . U.S. National Library of Medicine . Drug Information Portal .

Notes and References

1. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave JP, Yerly S, Bisset LR, Fischer M, Vernazza P, Bernasconi E, Battegay M, Ledergerber B, Günthard H, Howe C, Weber R, Perrin L . 6 . A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection . The Journal of Infectious Diseases . 185 . 9 . 1251–60 . May 2002 . 12001042 . 10.1086/340312 . free .
2. Web site: InPharm.com . GlaxoSmithKline-Pfizer launch HIV joint venture . https://web.archive.org/web/20120104114210/http://www.inpharm.com/news/glaxosmithkline-pfizer-launch-hiv-joint-venture . 4 January 2012 .
3. Web site: Trizivir- abacavir sulfate, lamivudine, and zidovudine tablet, film coated . DailyMed . 10 May 2019 . 7 April 2020.
4. Horvath T, Madi BC, Iuppa IM, Kennedy GE, Rutherford G, Read JS . Interventions for preventing late postnatal mother-to-child transmission of HIV . The Cochrane Database of Systematic Reviews . 1 . CD006734 . January 2009 . 2009 . 19160297 . 10.1002/14651858.CD006734.pub2 . 7389566 .
5. Web site: Drug Approval Package: Trizivir (abacavir sulfate, lamivudine, zidovudine) NDA #021205 . U.S. Food and Drug Administration (FDA) . 28 March 2004 . 7 April 2020.
6. Web site: Trizivir EPAR . European Medicines Agency (EMA) . 7 April 2020.
7. http://www.empr.com/lupin-launches-generic-trizivir/article/326146/ Monthly Prescribing Reference (MPR)
8. Web site: Abacavir Sulfate . Lupin Pharma .
9. Web site: Abacavir sulfate, lamivudine and zidovudine: FDA-Approved Drugs . U.S. Food and Drug Administration (FDA) . 6 July 2020.
10. Web site: Trizivir Medication Guide. ViiV Healthcare. March 2017. live. https://web.archive.org/web/20191222132400/https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021205s036lbl.pdf . 22 December 2019 .
11. Web site: Side Effects of Trizivir (Abacavir Sulfate, Lamivudine, and Zidovudine), Warnings, Uses. RxList. en. 22 December 2019.